Marianne Ziol

Marianne Ziol

Auto-generated profile, based on publicly available information

Marianne Ziol

Team « Functional Genomics of Solid Tumors », Cordeliers Research Center, Sorbonne Université, Inserm, Université Paris Cité, équipe Labellisée Ligue Contre le Cancer, Paris, France

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2003 in Ultrasound in Medicine & Biology
Verified
Journal Article
Closed access
LSLaurent Sandrin
Laurent Sandrin
BFBertrand Fourquet
Bertrand Fourquet
JHJean-Michel Hasquenoph
Jean-Michel Hasquenoph
SYSylvain Yon
Sylvain Yon
CFCéline Fournier
Céline Fournier
RPRobert Palau
Robert Palau

23 December 2004 in Hepatology
Verified
Journal Article
Open access
PDF file
MZMarianne Ziol
Marianne Ziol
AHAdriana Handra-Luca
Adriana Handra-Luca
AKAdrien Kettaneh
Adrien Kettaneh
CCChristos Christidis
Christos Christidis
FMFrédéric Mal
Frédéric Mal
MBMichel Beaugrand
Michel Beaugrand
Liver fibrosis is the main predictor of the progression of chronic hepatitis C, and its assessment by liver biopsy (LB) can help determine therapy. However, biopsy is an invasive procedure with several limitations. A new, noninvasive medical device based on transient elastography has been designed to measure liver stiffness. The aim of this study was to investigate the use of liver stiffness measurement (LSM) in the evaluation of liver fibrosis in patients with chronic hepatitis C. We prospectively enrolled 327 patients with chronic hepatitis C in a multicenter study. Patients underwent LB and LSM. METAVIR liver fibrosis stages were assessed on biopsy specimens by 2 pathologists. LSM was performed by transient elastography. Efficiency of LSM and optimal cutoff values for fibrosis stage assessment were determined by a receiver-operating characteristics (ROC) curve analysis and cross-validated by the jack-knife method. LSM was well correlated with fibrosis stage (Kendall correlation coefficient: 0.55; P < .0001). The areas under ROC curves were 0.79 (95% CI, 0.73-0.84) for F ≥ 2, 0.91 (0.87-0.96) for F ≥ 3, and 0.97 (0.93-1) for F = 4; for larger biopsies, these values were, respectively, 0.81, 0.95, and 0.99. Optimal stiffness cutoff values of 8.7 and 14.5 kPa showed F ≥ 2 and F = 4, respectively. In conclusion, noninvasive assessment of liver stiffness with transient elastography appears as a reliable tool to detect significant fibrosis or cirrhosis in patients with chronic hepatitis C. (Hepatology 2005;41:48–54.)

1 January 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
PNPierre Nahon
Pierre Nahon
VBValérie Bourcier
Valérie Bourcier
RLRichard Layese
Richard Layese
EAEtienne Audureau
Etienne Audureau
CCCarole Cagnot
Carole Cagnot
SHSophie Hillaire
Sophie Hillaire

6 January 2009 in Liver International
Verified
Journal Article
Closed access
PDF file
PMPatrick Marcellin
Patrick Marcellin
MZMarianne Ziol
Marianne Ziol
PBPierre Bedossa
Pierre Bedossa
CDCatherine Douvin
Catherine Douvin
RPRaoul Poupon
Raoul Poupon
MBMichel Beaugrand
Michel Beaugrand

28 November 2006 in Hepatology
Verified
Journal Article
Open access
PDF file
NGNathalie Ganne-Carrié
Nathalie Ganne-Carrié
MZMarianne Ziol
Marianne Ziol
VLVictor de Ledinghen
Victor de Ledinghen
CDCatherine Douvin
Catherine Douvin
PMPatrick Marcellin
Patrick Marcellin
MBMichel Beaugrand
Michel Beaugrand
A proper diagnosis of cirrhosis is essential for the management of patients with chronic liver diseases. We assessed the accuracy of liver stiffness measurement by Fibroscan for the diagnosis of cirrhosis in 1,257 patients with chronic liver diseases of various causes enrolled in a prospective multicenter study as well as clarified causes of discrepancies between liver histology and Fibroscan. One hundred thirty-two patients had unsuitable biopsy specimens, and 118 had unreliable liver stiffness measurements. Because 232 patients overlapped with a previous study, analysis was performed in the 775 new patients then derived in the whole population (1,007; 165 cirrhosis). Diagnostic accuracy was assessed by receiver operator curve (ROC) analysis. Liver samples were re-analyzed in case of discrepancies. The area under the ROC (AUROC) was 0.95 (95% CI, 0.93-0.96) for the diagnosis of cirrhosis in either 775 or 1,007 patients. The cutoff value with optimal diagnosis accuracy was 14.6 kPa in 1,007 patients (positive and negative predictive values, 74% and 96%) with discrepancies among the etiological groups. Eighty patients were misclassified: (1) among 45 patients without cirrhosis with liver stiffness 14.6 kPa or greater, 27 (60%) had extensive fibrosis and 10 (22%) significant perisinusoidal fibrosis; and (2) among 35 patients with cirrhosis and liver stiffness less than 14.6 kPa, 10 (29%) had a macronodular pattern and 25 (71%) either none or mild activity. In conclusion , Fibroscan is a reliable method for the diagnosis of cirrhosis in patients with chronic liver diseases, better at excluding than at predicting cirrhosis using a threshold of 14.6 kPa. False-negatives are mainly attributable to inactive or macronodular cirrhosis.

1 May 2006 in Hepatology
Verified
Journal Article
Closed access
PDF file
CCChristophe Corpechot
Christophe Corpechot
ANAhmed El Naggar
Ahmed El Naggar
APArmelle Poujol-Robert
Armelle Poujol-Robert
MZMarianne Ziol
Marianne Ziol
DWDominique Wendum
Dominique Wendum
RPRaoul Poupon
Raoul Poupon